We showed previously that the prognostic effect of BCL2 status is maximal in the first five years after a diagnosis of breast cancer and wanes thereafter, suggesting that its utility as a diagnostic adjunct may be limited to this period. The gene discussed is BCL2; the disease is breast cancer.